Source facts
FDA issued an approval letter for IDELALISIB on 2026-06-02. The source metadata identifies ANDA 216921 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
IDELALISIB — FDA Approval Letter (ANDA 216921)
Issued to NATCO. Application is approved as submitted.
Assyro regulatory brief
FreeWhat did FDA decide for IDELALISIB?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: ANDA 216921.
- 3Submission: original application.
- 4Sponsor: NATCO.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the IDELALISIB approval letter
Is IDELALISIB FDA approved?
This letter documents an FDA approval action: FDA approved ANDA 216921 for IDELALISIB, sponsored by NATCO, on June 2, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is ANDA 216921?
ANDA 216921 is the application under which FDA issued this approval letter for IDELALISIB to NATCO. The letter is dated June 2, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.